Axsome Therapeutics Inc. (AXSM) Rallies 10.11% After Earnings, EPS Below Consensus, Sales Miss Estimates

2026-05-04 · Stocks · QuoteReporter

Post Earning Analysis

Axsome Therapeutics Inc. (AXSM) Rallies 10.11% After Earnings, EPS Below Consensus, Sales Miss Estimates

Axsome Therapeutics, Inc. is a commercial-stage biopharmaceutical company founded in 2012, focused on developing innovative therapies for central nervous system disorders. Based in New York, NY, its product lineup features Auvelity and Sunosi, while its pipeline includes promising candidates like AXS-05, AXS-07, AXS-12, and AXS-14, addressing a range of neurological conditions.

Axsome Therapeutics has recently made significant announcements that could positively impact its stock. On May 4, 2026, Axsome reported its first-quarter financial results for the year and provided a business update, emphasizing its ongoing projects and financial health. Additionally, on the same day, Axsome's Q1 earnings snapshot was released, offering investors a detailed look at the company's financial performance.

Earlier in the week, on May 1, 2026, Axsome hosted an investor event to discuss the FDA approval of AUVELITY for the treatment of agitation associated with dementia in Alzheimer's patients. This event featured expert thought leaders and provided valuable insights into the drug's market potential and therapeutic impact.

Furthermore, on April 30, 2026, Axsome announced the FDA approval of AUVELITY, marking a significant milestone in the company's development pipeline. This approval could lead to increased market share and revenue, given the substantial need for effective treatments in Alzheimer's-related conditions.

These developments suggest a robust period for Axsome Therapeutics, potentially leading to increased investor confidence and positive stock movements.

The current price of the asset is $228.54, reflecting a significant increase of 10.11% today. This price is near its 52-week and year-to-date (YTD) high of $234.29, indicating a minor retracement of -2.45% from these peaks. The asset has shown remarkable growth from its 52-week low of $96.09 and YTD low of $79.19, with increases of 137.84% and 188.6% respectively, highlighting a strong bullish trend over the past year.

The asset's performance relative to its moving averages further underscores this bullish sentiment, with current prices exceeding the 20-day, 50-day, and 200-day moving averages by 22.06%, 32.41%, and 54.27% respectively. This suggests sustained upward momentum.

The Relative Strength Index (RSI) at 81.16 points to an overbought condition, which could signal a potential pullback or consolidation in the near term. Meanwhile, a positive Moving Average Convergence Divergence (MACD) value of 9.95 supports the strength of the current uptrend but also warrants caution due to the high RSI.

Overall, the asset's price trends suggest robust upward momentum, though the overbought condition may lead to short-term volatility or corrections.

Earnings Trend Table

The earnings per share (EPS) data across the quarters reveals a pattern of consistently negative EPS, indicating a period of financial challenges for the company. The trend shows fluctuations in both the magnitude of losses per share and the accuracy of EPS estimates.

From November 2023 to May 2026, the company's reported EPS was always worse than the estimates, except for two quarters (May 2025 and November 2024), where the reported EPS was slightly better than expected, as indicated by positive surprise percentages of 7.99% and 4.96%, respectively. This suggests occasional outperformance relative to analyst expectations.

The most significant discrepancy occurred in February 2024, where the reported EPS of -2.08 greatly exceeded the estimate of -1.17, resulting in a surprise percentage of -77.59%. This represents the quarter with the highest negative deviation from expectations, highlighting a particularly challenging period.

Overall, while there are instances where the company managed to perform better than anticipated, the general trend of underperformance and high volatility in EPS suggests operational or market challenges that affected financial outcomes more adversely than expected. This trend of negative EPS and often significant deviations from estimates could be indicative of underlying issues in predictability and stability in the company's financial performance.

The most recent analysis of rating changes for the subject entity includes four significant adjustments from respected financial firms.

1. Wolfe Research - February 24, 2026:
   Wolfe Research initiated coverage on the entity with an "Outperform" rating, assigning a target price of $230. This initiation suggests a positive outlook from Wolfe Research, indicating an expectation of the entity's performance to surpass the general market or sector average.

2. Morgan Stanley - January 08, 2026:
   Morgan Stanley downgraded their rating from "Overweight" to "Equal-Weight" with a revised target price of $204. This change implies a neutral stance, suggesting that Morgan Stanley forecasts the entity's market performance to align closely with the sector average, adjusting down from a previously more bullish expectation.

3. B. Riley Securities - October 01, 2025:
   B. Riley Securities initiated coverage with a "Buy" rating and set a target price of $179. The "Buy" status indicates a strong positive outlook, reflecting B. Riley's confidence in the entity's potential for above-average market performance.

4. Wells Fargo - September 03, 2025:
   Wells Fargo resumed coverage with an "Overweight" rating, placing a target price of $163. The "Overweight" rating suggests that Wells Fargo views the entity as likely to outperform its peers or the sector average.

These changes reflect a mix of optimism and cautious reevaluation, with the most recent ratings indicating a generally positive but varied perspective on the entity's future market performance.

The current price of the stock stands at $228.54. This price is notably higher than the average target price provided by various analysts over recent months, which suggests a potential overvaluation according to some analysts' expectations. The highest target price of $230 from Wolfe Research only slightly exceeds the current market price, indicating minimal expected upside from their perspective. On the other hand, the lowest target price from Wells Fargo at $163 significantly undercuts the current price, highlighting a more bearish outlook.

The range of analyst ratings and target prices from $163 to $230 reflects a varied perception of the stock's future performance. Notably, Morgan Stanley's recent downgrade from "Overweight" to "Equal-Weight" with a target price of $204 suggests a shift towards a more cautious stance on the stock. This mixed analyst sentiment, alongside the current trading price, may indicate that the stock is currently viewed as less favorable for aggressive investment, with expectations leaning towards stabilization or modest growth at best.

Disclaimer: The information provided here is for educational and informational purposes only and should not be interpreted as financial advice, investment recommendations, or trading guidance. Markets involve risk, and past performance is not indicative of future results. You should always conduct your own research and consult with a qualified financial advisor before making any investment decisions. By acting, you accept full responsibility for your choices.